Synopsis

We understand that registering for a conference is not essential right now and many researchers will be unable to register for a future conference of interest if their university or lab is temporarily closed. Therefore, you can simply register your interest here to be kept updated with details about this conference without committing to attending and our team will keep in touch with you regarding deadline reminders and grant opportunities. We hope this service is of use at this difficult time.

Alzheimer’s disease (AD) is the most common age-dependent neurodegenerative disease, which affects over 5 million people in the US and over 35 million people worldwide. Currently, only four drugs are approved for alleviating symptoms in AD patients, and no new therapy has been approved for AD by FDA since 2003. Other related neurodegenerative diseases such as Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS) are also age-dependent and lack effective therapies. Hence, finding cures for AD and other related neurodegenerative diseases is urgent and various approaches should be actively pursued. This planned conference intends to bring leading scientists and clinicians from all over the world to present their unpublished observations or findings to attendees and to share their vision or prospects on translational research. We expect that some presenters, either by talks or posters, will discuss our current state of knowledge in disease mechanisms, novel targets, new genetic association or pathways, approaches for identifying new therapeutic targets, and biomarkers for diagnosis or treatment readouts. We will also invite speakers who are conducting later stages of drug discoveries to share clinical trial results. The talks and poster presentations will include the most updated therapeutic strategies, newly discovered therapeutic targets, and recent clinical developments at various stages in the area of Alzheimer’s and related neurodegenerative diseases.  

Key topics of discussion will include:

• BACE1 inhibitors and/or γ-secretase modulators for reducing amyloid deposition 
• Active and passive vaccination for enhancing clearance of amyloid plaques
• Vaccines for reducing tau pathology
• Antisense approaches for AD, PD and ALS therapy
• Neural stem cell approaches for neurodegeneration
• Inflammatory modulators for neurodegeneration.
• Genetic linkage study and big data approaches
• Novel therapeutic targets

The significance of having this conference is to provide a unique forum for the research community focusing on translational studies geared towards therapies in AD and related neurodegenerative diseases to come together and to discuss the latest advances and the future challenges in the field.  It will also facilitate interactions between junior scientists and leading investigators in a relatively small conference setting. 

Student Offer

Take advantage of this fantastic opportunity for students! Register an academic at the early bird rate and bring a student for only €830. Unfortunately, Postdocs are not eligible. Both registration packages include; accommodation for the 25, 26, 27 July (on a shared basis for students) and a food and beverage package for the conference period. Academic registrations must be completed by 08 Feb 2021. Once registered, please contact (Emily Meen) to obtain a special registration link for your student. 

Target Audience

To bring junior investigators from academic labs and industries to present and closely interact with leading scientists in the field. We anticipate international representation from the US, Europe, Canada, Japan, Korea, China, and others. 

Educational Need

Junior investigators such as graduate students or postdoctoral fellows as well as clinician scientists are expected to gain knowledge on the most current therapeutic strategies in AD and the related field.